Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nervijen is a multi-ingredient pharmaceutical product developed and marketed by Jenburkt Pharmaceuticals, primarily indicated for the management of peripheral neuropathy, including diabetic neuropathy. The formulation typically consists of **methylcobalamin** (an active form of Vitamin B12), **alpha lipoic acid** (thioctic acid), **pyridoxine** (Vitamin B6), and **folic acid**. Methylcobalamin acts as a cofactor for methionine synthase, which is essential for the synthesis of myelin and the regeneration of damaged neurons. Alpha lipoic acid serves as a potent antioxidant and a mitochondrial cofactor that helps reduce oxidative stress and improve nerve conduction velocity. Pyridoxine and folic acid support essential metabolic pathways and DNA repair mechanisms necessary for maintaining neuronal health. While primarily available as an oral capsule, the Nervijen brand also includes injectable formulations and variants with additional ingredients like benfotiamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylcobalamin + alpha lipoic acid + pyridoxine + folic acid.